Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)Seeking Alpha • 04/17/25
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study SetbackZacks Investment Research • 04/15/25
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped TodayThe Motley Fool • 04/14/25
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?The Motley Fool • 04/02/25
Viking Therapeutics, Inc. (VKTX) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 04/01/25
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss DrugZacks Investment Research • 03/27/25
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill StudyInvestors Business Daily • 03/26/25
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with ObesityPRNewsWire • 03/26/25
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should KnowZacks Investment Research • 03/24/25
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?The Motley Fool • 03/19/25